Top

Published in:

Open Access 04-05-2023 | Platelet Aggregation Inhibitor | Original Article

Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients

Authors: Kathrin Bausch, Leutrim Zahiti, Michel Schrutt, Christian Wetterauer, Florian Samuel Halbeisen, Jan Ebbing, Hans-Helge Seifert

Published in: World Journal of Urology | Issue 6/2023

Abstract

Purpose

This study assessed the efficacy, safety and durability outcomes of water vapor thermal therapy with Rezum in a real-world cohort of patients with lower urinary tract symptoms due to benign prostate obstruction.

Methods

Consecutive, unselected patients undergoing Rezum treatment between January 2014 and August 2022 were candidates for this pragmatic, observational, longitudinal, single-center cohort study. Pre- and perioperative data were descriptively summarized. The primary outcome was surgical efficacy, determined by International Prostate Symptom Score (IPSS), Quality of Life (QoL) Score, maximum urinary flow rate (Qmax), post-void residual (PVR) volume and prostate volume (PV) at baseline, 2 months, 6 months, 1 year, 2 years, and > 2 years.

Results

A total of 211 patients were enrolled for analysis. Overall, catheter removal was successful in 92.4% of patients after a median of 5 days. A preoperative catheter and the presence of a median lobe increased the risk of unsuccessful catheter removal. In total, 5.7% of patients were reoperated after a median of 407 days. Comparing baseline to the longest median follow-up, the postoperative IPSS decreased significantly by 65.7%, the QoL Score declined by 66.7% (both until a maximum median of 4.5 years) and Qmax improved by 66.7% (until 3.9 years). Post-void residual volume and PV were reduced by 85.7% (3.7 years) and 47% (4.0 years), respectively. Clavien–Dindo complication ≤ II occurred in 11.8%.

Conclusion

Rezum is a safe minimally invasive treatment option in a real-world patient cohort with a beneficial improvement of micturition symptoms and voiding function during follow-up.

Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ (2006) An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12(4 Suppl):S83–S89PubMed

Vanderweyde T, Bednar MM, Forman SA, Wolozin B (2010) Iatrogenic risk factors for Alzheimer’s disease: surgery and anesthesia. J Alzheimer’s Dis JAD 22(Suppl 3):91–104. https://doi.org/10.3233/JAD-2010-100843CrossRefPubMed

McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Rousseau M, Beahrs JR, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Larson TR, Dixon CM, Roehrborn CG (2016) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 195(5):1529–1538. https://doi.org/10.1016/j.juro.2015.10.181CrossRefPubMed

McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041CrossRefPubMed

McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Pliskin M, Beahrs JR, Prall D, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Tadros NN, Gange SN, Roehrborn CG (2021) Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 206(3):715–724. https://doi.org/10.1097/JU.0000000000001778CrossRefPubMed

Siena G, Cindolo L, Ferrari G, Maruzzi D, Fasolis G, Condorelli SV, Varvello F, Visalli F, Rabito S, Toso S, Caroassai S, Mari A, Viola L, Somani BK, Carini M (2021) Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol 39(10):3875–3880. https://doi.org/10.1007/s00345-021-03642-4CrossRefPubMedPubMedCentral

Alegorides C, Fourmarier M, Eghazarian C, Lebdai S, Chevrot A, Droupy S (2020) Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one year. Progres en urologie : journal de l’Association francaise d’urologie et de la Societe francaise d’urologie 30(12):624–631. https://doi.org/10.1016/j.purol.2020.05.004CrossRefPubMed

Johnston MJ, Noureldin M, Abdelmotagly Y, Paramore L, Gehring T, Nedas TG, Rajkumar G, Emara A, Hindley RG (2020) Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int 126(5):557–558. https://doi.org/10.1111/bju.15203CrossRefPubMed

Bole R, Gopalakrishna A, Kuang R, Alamiri J, Yang DY, Helo S, Ziegelmann MJ, Köhler TS (2020) Comparative postoperative outcomes of Rezūm prostate ablation in patients with large versus small glands. J Endourol 34(7):778–781. https://doi.org/10.1089/end.2020.0177CrossRefPubMed

10.

McVary KT, Holland B, Beahrs JR (2020) Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 23(2):303–308. https://doi.org/10.1038/s41391-019-0187-5CrossRefPubMed

11.

Dixon CM, RijoCedano E, Mynderse LA, Larson TR (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7:13–18. https://doi.org/10.2147/RRU.S74040CrossRefPubMedPubMedCentral

12.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.aeCrossRefPubMedPubMedCentral

13.

Ines M, Babar M, Singh S, Iqbal N, Ciatto M (2021) Real-world evidence with The Rezūm system: a retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. Prostate 81(13):956–970. https://doi.org/10.1002/pros.24191CrossRefPubMed

14.

Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G, Wagrell L, Tornblom M, Cedano ER, Woodrum DA, Dixon CM, Larson TR (2015) Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86(1):122–127. https://doi.org/10.1016/j.urology.2015.03.021CrossRefPubMed

15.

Miller LE, Chughtai B, Dornbier RA, McVary KT (2020) Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol 204(5):1019–1026. https://doi.org/10.1097/JU.0000000000001132CrossRefPubMed

16.

Abt D, Müllhaupt G, Hechelhammer L, Markart S, Güsewell S, Schmid HP, Mordasini L, Engeler DS (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol 80(1):34–42. https://doi.org/10.1016/j.eururo.2021.02.008CrossRefPubMed

17.

Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C (2020) Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 27(1):10072–10079PubMed

18.

Vandenbroucke JP, von Elm E, Altman DG et al (2014) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 12:1500–1524. https://doi.org/10.1016/j.ijsu.2014.07.014CrossRefPubMed

Title: Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients
Authors: Kathrin Bausch
Leutrim Zahiti
Michel Schrutt
Christian Wetterauer
Florian Samuel Halbeisen
Jan Ebbing
Hans-Helge Seifert
Publication date: 04-05-2023
Publisher: Springer Berlin Heidelberg
Keywords: Platelet Aggregation Inhibitor
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Thermal Therapy
Published in: World Journal of Urology / Issue 6/2023
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04395-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2023

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

Increased intrarenal pressure and lack of experience may worsen retrograde intrarenal surgery outcomes

Lowering the percent body fat in the obese population might reduce male lower urinary tract symptoms

Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis

Eliciting men’s preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis

Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy